Susan M McAllister1, Raspati C Koesoemadinata2,3, Prayudi Santoso2,4, Nanny N M Soetedjo2,4, Abdul Kamil2, Hikmat Permana4, Rovina Ruslami2,5, Julia A Critchley6, Reinout van Crevel7, Philip C Hill1, Bachti Alisjahbana2,4. 1. Centre for International Health, University of Otago Medical School, University of Otago, P.O. Box 56, Dunedin, New Zealand. 2. Infectious Disease Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. 3. Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Internal Medicine, Nijmegen, The Netherlands. 4. Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran - Hasan Sadikin General Hospital, Bandung, Indonesia. 5. Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. 6. Population Health Research Institute, St Georges, University of London, London, SW 17 ORE, UK. 7. Radboud University Medical Centre, Department of Internal Medicine and Radboud Centre of Infectious Diseases, 6500 HB Nijmegen, The Netherlands.
Abstract
BACKGROUND: Data regarding the incidence of tuberculosis (TB) among people living with diabetes (PLWD) in TB-endemic settings are scarce. We examined TB incidence among PLWD in Indonesia who had previously been screened for latent TB infection (LTBI) and TB disease. METHODS: PLWD (≥18 y of age) in an urban setting were examined a mean 3.4 y after they had been screened for active TB and LTBI. Data on subsequent TB diagnosis were collected by interview and with chest X-ray, sputum smear and Mycobacterium tuberculosis culture. TB incidence rates were stratified for baseline LTBI status, as determined by the QuantiFERON interferon-gamma release assay (IGRA). RESULTS: Of 590 PLWD, 101 had died and 163 could not be contacted or refused. Among the 326 who were re-examined, 6 (1.8%; 95% confidence interval [CI] 0.7 to 4.0) reported being diagnosed already and a further 5 were diagnosed with active TB (1.5%; 95% CI 0.50 to 3.5). The TB incidence rate was 9.85 (95% CI 4.03 to 15.68) per 1000 person-years. TB incidence was higher among PLWD with baseline LTBI (17.13; 95% CI 5.25 to 29.00/1000 person-years) compared with those without LTBI (4.79; 95% CI -0.63 to 10.21), with an incidence rate ratio of 3.57 (95% CI 0.86 to 20.92; p=0.054). CONCLUSIONS: PLWD with LTBI in Indonesia and similar settings are likely to benefit from TB preventive therapy.
BACKGROUND: Data regarding the incidence of tuberculosis (TB) among people living with diabetes (PLWD) in TB-endemic settings are scarce. We examined TB incidence among PLWD in Indonesia who had previously been screened for latent TB infection (LTBI) and TB disease. METHODS: PLWD (≥18 y of age) in an urban setting were examined a mean 3.4 y after they had been screened for active TB and LTBI. Data on subsequent TB diagnosis were collected by interview and with chest X-ray, sputum smear and Mycobacterium tuberculosis culture. TB incidence rates were stratified for baseline LTBI status, as determined by the QuantiFERON interferon-gamma release assay (IGRA). RESULTS: Of 590 PLWD, 101 had died and 163 could not be contacted or refused. Among the 326 who were re-examined, 6 (1.8%; 95% confidence interval [CI] 0.7 to 4.0) reported being diagnosed already and a further 5 were diagnosed with active TB (1.5%; 95% CI 0.50 to 3.5). The TB incidence rate was 9.85 (95% CI 4.03 to 15.68) per 1000 person-years. TB incidence was higher among PLWD with baseline LTBI (17.13; 95% CI 5.25 to 29.00/1000 person-years) compared with those without LTBI (4.79; 95% CI -0.63 to 10.21), with an incidence rate ratio of 3.57 (95% CI 0.86 to 20.92; p=0.054). CONCLUSIONS: PLWD with LTBI in Indonesia and similar settings are likely to benefit from TB preventive therapy.
Authors: F Naufal; L H Chaisson; K O Robsky; P Delgado-Barroso; H S Alvarez-Manzo; C R Miller; A E Shapiro; J E Golub Journal: Int J Tuberc Lung Dis Date: 2022-06-01 Impact factor: 3.427
Authors: Nyanda Elias Ntinginya; Lindsey Te Brake; Philip C Hill; Reinout van Crevel; Issa Sabi; Nyasatu Chamba; Kajiru Kilonzo; Sweetness Laizer; Irene Andia-Biraro; Davis Kibirige; Andrew Peter Kyazze; Sandra Ninsiima; Julia A Critchley; Renee Romeo; Josephine van de Maat; Willyhelmina Olomi; Lucy Mrema; David Magombola; Issakwisa Habakkuk Mwayula; Katrina Sharples Journal: Trials Date: 2022-06-10 Impact factor: 2.728
Authors: R C Koesoemadinata; S M McAllister; N N M Soetedjo; P Santoso; R Ruslami; H Damayanti; N Rahmadika; B Alisjahbana; R van Crevel; P C Hill Journal: Public Health Action Date: 2021-12-21
Authors: Anthony D Harries; Ajay M V Kumar; Srinath Satyanarayana; Pruthu Thekkur; Yan Lin; Riitta A Dlodlo; Mohammed Khogali; Rony Zachariah Journal: Trop Med Infect Dis Date: 2020-04-16